Drug Makers Settle Suit Over Epilepsy Treatment

Law360, New York (July 2, 2007, 12:00 AM EDT) -- Kali Laboratories Inc. will not be able to introduce a generic version of a Valeant Pharmaceuticals International epileptic seizure treatment for more than three years under a patent infringement settlement announced Monday.

Under the agreement, Kali may not introduce a generic version of Diastate and Diastate AcuDial until September 2010. Other terms of the settlement, which was reached last week at a conference in a New Jersey court, were not disclosed. The companies have 60 days to finalize the agreement.

Xcel Pharmaceuticals, which was acquired by...
To view the full article, register now.